Novel trial designs: which agents and how do we test them?
Over the last decade, an increasing number of novel therapies have been tested in prostate cancer. Although each agent has potential to affect the natural history of the disease, how we should proceed, select, and test these agents to show a clinical benefit remains a dilemma. Because prostate cancer is a heterogeneous disease, an understanding of the disease states is required to screen and test novel agents. Only with the appropriate selection of disease state, trial design, and endpoints will we be able to select the most promising regimens to move forward.
Kelly
William Kevin
WK
Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. kellyw@mskcc.org
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D006728:Hormones / Q000008:administration & dosage; D006801:Humans; D008297:Male; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000378:metabolism; D012107:Research Design
D006728:Hormones; D017430:Prostate-Specific Antigen